AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (Canceled)

11. (Currently amended) The haemostatic composition according to claim [[10]] 106, wherein the ratio between the water absorbed by the haemostatic sponge according to claim [[10]] 106 and the water absorbed by a conventional absorbable gelatin sponge is at the most 0.95.

12-13. (canceled)

14. (Currently amended) The haemostatic composition according to claim [[1]] 103, wherein said composition is in the form of a haemostatic sponge, wherein at least one of the surfaces of the haemostatic sponge is covered by a top sheet.

15. (Previously presented) The haemostatic composition according to claim 14, wherein the top sheet is removable.

16. (Canceled)

17. (Currently amended) The haemostatic composition according to claim [[1]] 103, wherein said composition is dry.

18. (Currently amended) A haemostatic paste prepared by pre-wetting the haemostatic composition according to claim [[1]] 103 with a liquid to create a paste, wherein [[said]] a haemostatic composition is in the form of a powder or flakes.

19-22. (canceled)

23. (Withdrawn/Currently amended) A method for producing a cross-linked and sterile haemostatic composition comprising the steps of:

i) mixing ~~a biologically absorbable material~~ gelatine and hyaluronic acid or a hyaluronate salt derivative thereof, and a solvent, and

ii) treating the mixture obtained in step i) with dry heat at a temperature between 110-200°C.

24. (Withdrawn) The method according to claim 23, wherein said method comprises a further step of drying the mixture obtained in step i) before treating the mixture with dry heat at a temperature between 110-200°C according to step ii).

25-26. (canceled)

27. (Withdrawn/Currently amended) A method for preparing the haemostatic composition according to claim 17, said method comprising the steps of:

i) mixing gelatin, hyaluronic acid (HA) or a hyaluronate salt derivative thereof, and a solvent;

ii) cross-linking said composition with dry heat at 110-200°C; and

iii) drying said mixture.

28. (Canceled)

29. (Withdrawn/Currently amended) A method according to claim 23, wherein the mixing of ~~the biologically absorbable material~~ gelatine, hyaluronic acid (HA) or a hyaluronate salt derivative thereof, and a solvent is performed by any of the following alternatives:

a) Mixing ~~a biologically absorbable material~~ gelatine with hyaluronic acid (HA) or a hyaluronate salt derivative thereof and subsequently adding a solvent;

b) mixing a solution of ~~a biologically absorbable material~~ gelatine with a solution of hyaluronic acid (HA) or a hyaluronate salt derivative thereof;

c) mixing ~~a biologically absorbable material~~ gelatine with a solution of hyaluronic acid (HA) or a hyaluronate salt derivative thereof;

d) mixing a solution of ~~a biologically absorbable material~~ gelatine with hyaluronic acid (HA) or a hyaluronate salt derivative thereof.

30. (Withdrawn) The method according to any of claims 23 or 27, wherein said mixing is performed under mechanical influence.

31-35. (Canceled)

36. (Withdrawn / Currently amended) The method according to any of claims 23 or 27, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is provided in the form of a gel.

37. (Withdrawn / Currently amended) The method according to any of claims 24 or 27, wherein said drying is performed at a temperature from ~~about~~ 20°C to ~~about~~ 40°C~~, or at about 30 °C~~.

38. (Withdrawn / Currently amended) The method according to any of claims 24 or 27, wherein said drying is conducted for ~~about~~ 6 to ~~about~~ 24 hours~~, or for about 16 hours~~.

39. (Withdrawn) The method according to any of claims 24 or 27, wherein said drying is performed by freeze-drying.

40. (Canceled)

41. (Withdrawn) The method according to any of claims 23 or 27 wherein said mixing is performed by whipping, stirring, spinning, static mixing, motionless mixing or centrifugation.

42-47. (Canceled)

48. (Currently amended) The haemostatic composition according to claim [[5]] 103, wherein said composition comprises ~~amount of gelatin is~~ at the most 85% (w/w) of said gelatin.

49. (Canceled)

50. (Currently amended) The haemostatic composition according to claim [[5]] 103, wherein said composition comprises ~~amount of gelatin is~~ at the most 75% (w/w) of said gelatin.

51. (Currently amended) The haemostatic composition according to claim [[5]] 103, wherein said composition comprises ~~amount of gelatin is~~ at the most 70% (w/w) of said gelatin.

52. (Currently amended) The haemostatic composition according to claim [[5]] 103, wherein said composition comprises ~~amount of gelatin is~~ at the most 65% (w/w) of said gelatin.

53. (Currently amended) The haemostatic composition according to claim [[5]] 103, wherein said composition comprises ~~amount of gelatin is~~ at the most 60% (w/w) of said gelatin.

54. (Currently amended) The haemostatic composition according to claim [[1]] 103, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is incorporated into said composition to a final content of at least 15% (w/w).

55. (Canceled)

56. (Currently amended) The haemostatic composition according to claim [[1]] 103, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is incorporated into said composition to a final content of at least 25% (w/w).

57. (Currently amended) The haemostatic composition according to claim [[1]] 103, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is incorporated into said composition to a final content of at least 30% (w/w).

58. (Currently amended) The haemostatic composition according to claim [[1]] 103, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is incorporated into said composition to a final content of at least 35% (w/w).

59. (Currently amended) The haemostatic composition according to claim [[1]] 103, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is incorporated into said composition to a final content of at least 40% (w/w).

60. (Canceled)

61. (Currently amended) The haemostatic composition according to claim [[1]] 103, wherein the hyaluronic acid (HA) is physically cross-linked.

62. (Currently amended) The haemostatic composition according to claim [[1]] 103, wherein the hyaluronic acid (HA) has a pH value in the range of from 5 to 9.

63-100. (Canceled)

101. (Currently amended) A thermally cross-linked and sterile haemostatic composition comprising gelatin and hyaluronic acid (HA) or a hyaluronate salt derivative thereof, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is incorporated into said composition to a final content of at least 10% (w/w) and at most 90% (w/w), and wherein said gelatin is incorporated into said composition to a final content of at least 10% (w/w) and at most 90% (w/w), and wherein said composition does not comprise a chemical cross-linking agent or residues thereof.

102. (Currently amended) A thermally cross-linked haemostatic composition comprising gelatin and hyaluronic acid (HA) or a hyaluronate salt derivative thereof, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof is incorporated into said haemostatic composition to a final content of at least 10% (w/w) hyaluronic acid (HA) or a

hyaluronate salt derivative thereof, and wherein said haemostatic composition does not comprise a chemical cross-linking agent or residues thereof.

103. (Currently amended) A sterile haemostatic composition comprising gelatin and hyaluronic acid (HA) or a hyaluronate salt derivative thereof, wherein said gelatin and hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is stabilized with dry heat at 110-200°C, and wherein said haemostatic composition does not comprise a chemical cross-linking agent or residues thereof.

104. (Currently amended) A haemostatic composition comprising gelatin and hyaluronic acid (HA) or a hyaluronate salt derivative thereof, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof is incorporated into said haemostatic composition to a final content of at least 10% (w/w) hyaluronic acid (HA) or a hyaluronate salt derivative thereof, and wherein said haemostatic composition is stabilized with dry heat, and wherein said haemostatic composition does not comprise a chemical cross-linking agent or residues thereof.

105. (Previously presented) The haemostatic composition according to any of claims 101-104, wherein said composition is in the form of a sponge, powder or flakes.

106. (Previously presented) The haemostatic composition according to claim 105, wherein said composition is in the form of a haemostatic sponge and wherein said sponge absorbs less water than an absorbable gelatin sponge.

107. (Previously presented) The haemostatic composition according to any of claims 101-104, wherein said composition comprises at the most 80% (w/w) of said gelatin.

108. (Currently amended) The haemostatic composition according to any of claims 101-104, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is incorporated into said composition to a final content of at least 20% (w/w).

109. (Previously presented) The haemostatic composition according to any of claims 101-102, wherein said composition is treated with dry heat.

110. (Currently amended) The haemostatic composition according to claim [[1]] 103, wherein said dry heat treatment at 110-200°C is conducted for 15 minutes to 6 hours.

111. (Withdrawn) A method for promoting haemostasis in an individual in need thereof, said method comprising the step of applying the haemostatic composition according to any of claims 101-104, onto at least a portion of an area where bleeding is present.

112. (Withdrawn/Currently amended) The haemostatic composition according to any of claims 101-104 further comprising ~~A method of delivering~~ an agent for delivery to ~~an intended~~ local site of a patient, wherein said haemostatic composition is in the form of a sponge~~, said method comprising the step of including the agent in the composition of any of claims 101-104, and delivering the agent to the local site of the patient.~~

113. (Withdrawn) A method for arresting bleeding in an individual in need thereof, said method comprising the step of applying to the site of bleeding the haemostatic composition according to any of claims 101-104.